BR112012017243A2 - constructos terapêuticos de apirase, agentes de apirase, e métodos de produção - Google Patents

constructos terapêuticos de apirase, agentes de apirase, e métodos de produção

Info

Publication number
BR112012017243A2
BR112012017243A2 BR112012017243A BR112012017243A BR112012017243A2 BR 112012017243 A2 BR112012017243 A2 BR 112012017243A2 BR 112012017243 A BR112012017243 A BR 112012017243A BR 112012017243 A BR112012017243 A BR 112012017243A BR 112012017243 A2 BR112012017243 A2 BR 112012017243A2
Authority
BR
Brazil
Prior art keywords
apyrase
constructs
methods
therapeutic
agents
Prior art date
Application number
BR112012017243A
Other languages
English (en)
Portuguese (pt)
Inventor
Chen Ridong
Seog Jeong Soon
Original Assignee
Apt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apt Therapeutics Inc filed Critical Apt Therapeutics Inc
Publication of BR112012017243A2 publication Critical patent/BR112012017243A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112012017243A 2010-01-13 2011-01-13 constructos terapêuticos de apirase, agentes de apirase, e métodos de produção BR112012017243A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29469510P 2010-01-13 2010-01-13
PCT/US2011/021187 WO2011088244A1 (en) 2010-01-13 2011-01-13 Therapeutic apyrase constructs, apyrase agents, and production methods

Publications (1)

Publication Number Publication Date
BR112012017243A2 true BR112012017243A2 (pt) 2017-09-19

Family

ID=44304650

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017243A BR112012017243A2 (pt) 2010-01-13 2011-01-13 constructos terapêuticos de apirase, agentes de apirase, e métodos de produção

Country Status (10)

Country Link
US (1) US8771683B2 (https=)
EP (1) EP2523971B1 (https=)
JP (1) JP5913130B2 (https=)
KR (1) KR20130009744A (https=)
AU (1) AU2011205248A1 (https=)
BR (1) BR112012017243A2 (https=)
CA (1) CA2787016C (https=)
IL (1) IL220882A0 (https=)
RU (1) RU2012134366A (https=)
WO (1) WO2011088244A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2941254B1 (en) * 2014-03-12 2017-01-11 Shiseido Company, Ltd. Agent for sedating response to external stimulation in skin and method for sedating that response technical field
CN105018442A (zh) * 2014-04-23 2015-11-04 Apt治疗公司 改进的en-腺苷三磷酸双磷酸酶
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CA3098818A1 (en) 2020-08-19 2022-02-19 Astrazeneca Ab Combination treatment
JP7547996B2 (ja) * 2020-12-22 2024-09-10 トヨタ自動車株式会社 コイルの製造方法
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
KR100545945B1 (ko) * 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP1733045A4 (en) 2004-02-27 2008-08-13 Apt Therapeutics Inc DESIGN AND THERAPEUTIC USE OF ADPASE-ENHANCED APYRASES
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法

Also Published As

Publication number Publication date
EP2523971A4 (en) 2013-06-05
EP2523971B1 (en) 2015-02-25
RU2012134366A (ru) 2014-02-20
AU2011205248A1 (en) 2012-08-02
JP5913130B2 (ja) 2016-04-27
CA2787016C (en) 2018-01-23
US8771683B2 (en) 2014-07-08
CA2787016A1 (en) 2011-07-21
EP2523971A1 (en) 2012-11-21
JP2013516991A (ja) 2013-05-16
KR20130009744A (ko) 2013-01-23
US20130142775A1 (en) 2013-06-06
WO2011088244A1 (en) 2011-07-21
IL220882A0 (en) 2012-09-24

Similar Documents

Publication Publication Date Title
BR112012017243A2 (pt) constructos terapêuticos de apirase, agentes de apirase, e métodos de produção
PH12014501091A1 (en) Binding molecules for bcma and cd3
PH12015501672A1 (en) Binding molecules for bcma and cd3
IL189994A0 (en) Production and purification of il-29
EA201691109A1 (ru) Химерные и гибридные полипептиды фактора viii-fc и способы их применения
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
CR20110619A (es) Produccion recombinante de peptidos
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
IN2014CN04586A (https=)
EA201400709A1 (ru) Молекула биспецифического антитела
GB201020995D0 (en) Biological materials and uses thereof
EA201291480A1 (ru) Фактор ix полипептиды и способы их использования
MX2009002388A (es) Uso de celulas humanas originarias de leucemia mieloide para la expresion de anticuerpos.
MX2012011405A (es) Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
BR112014008061A2 (pt) método para a produção enzimática de butadieno
CL2011001296A1 (es) Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales.
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
IN2014CN00597A (https=)
IN2014CN00650A (https=)
GB201214580D0 (en) Benzocyanine compounds
NZ719881A (en) Plant cytochrome p450
PH12014500771A1 (en) Enzyme cocktails prepared from mixed cultures
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
EA201101626A1 (ru) Бактерии с высокоэффективным метаболизмом
IN2014DN06660A (https=)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]